Literature DB >> 22379084

A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Antonio J Acosta-Hoyos1, Suzanne E Matsuura, Peter R Meyer, Walter A Scott.   

Abstract

Resistance to nucleoside reverse transcriptase (RT) inhibitors is conferred on human immunodeficiency virus type 1 through thymidine analogue resistance mutations (TAMs) that increase the ability of RT to excise chain-terminating nucleotides after they have been incorporated. The RT mutation M184V is a potent suppressor of TAMs. In RT containing TAMs, the addition of M184V suppressed the excision of 3'-deoxy-3'-azidothymidine monophosphate (AZTMP) to a greater extent on an RNA template than on a DNA template with the same sequence. The catalytically inactive RNase H mutation E478Q abolished this difference. The reduction in excision activity was similar with either ATP or pyrophosphate as the acceptor substrate. Decreased excision of AZTMP was associated with increased cleavage of the RNA template at position -7 relative to the primer terminus, which led to increased primer-template dissociation. Whether M184V was present or not, RT did not initially bind at the -7 cleavage site. Cleavage at the initial site was followed by RT dissociation and rebinding at the -7 cleavage site, and the dissociation and rebinding were enhanced when the M184V mutation was present. In contrast to the effect of M184V, the K65R mutation suppressed the excision activity of RT to the same extent on either an RNA or a DNA template and did not alter the RNase H cleavage pattern. Based on these results, we propose that enhanced RNase H cleavage near the primer terminus plays a role in M184V suppression of AZT resistance, while K65R suppression occurs through a different mechanism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22379084      PMCID: PMC3347382          DOI: 10.1128/JVI.05767-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations.

Authors:  Fernando A Frankel; Cédric F Invernizzi; Maureen Oliveira; Mark A Wainberg
Journal:  AIDS       Date:  2007-03-30       Impact factor: 4.177

2.  The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Authors:  H Q Gao; P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Mol Biol       Date:  2000-07-07       Impact factor: 5.469

3.  Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

4.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.

Authors:  Luis R Miranda; Matthias Götte; Fei Liang; Daniel R Kuritzkes
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

Authors:  Adrian S Ray; Aravind Basavapathruni; Karen S Anderson
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

8.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

9.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

10.  Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.

Authors:  Jessica Radzio; Nicolas Sluis-Cremer
Journal:  Retrovirology       Date:  2011-08-22       Impact factor: 4.602

View more
  3 in total

1.  Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.

Authors:  Moisés A Árquez; Samara Martín-Alonso; Robert J Gorelick; Walter A Scott; Antonio J Acosta-Hoyos; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  NRTI backbone in HIV treatment: will it remain relevant?

Authors:  Randall Tressler; Catherine Godfrey
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

3.  Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.

Authors:  Paul L Boyer; Kevin Melody; Steven J Smith; Linda L Dunn; Chris Kline; Douglas K Fischer; Richa Dwivedi; Pat Clark; Stephen H Hughes; Zandrea Ambrose
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.